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ABSTRACT
Introduction: Exenatide is a glucagon-like
peptide-1 receptor agonist (GLP-1 RA),
approved for treatment of type 2 diabetes
mellitus (T2DM). There is limited direct
evidence comparing the efficacy and
tolerability of exenatide 2 mg once weekly
(QW) to other GLP-1 RAs. A network
meta-analysis (NMA) was conducted to
estimate the relative efficacy and tolerability of
exenatide QW versus other GLP-1 RAs for the
treatment of adults with T2DM inadequately
controlled on metformin monotherapy.
Methods: A systematic literature review was
conducted to identify randomized controlled
trials (RCTs) that investigated GLP-1 RAs
(albiglutide, dulaglutide, exenatide, liraglutide,
and lixisenatide) at approved doses in the
United States/Europe, added on to metformin
only and of 24 ± 6 weeks treatment duration.
A Bayesian NMA was conducted.
Results: Fourteen RCTs were included in the
NMA. Exenatide QW obtained a statistically
significant reduction in glycated hemoglobin
(HbA1c) relative to lixisenatide 20 lg once
daily. No other comparisons of exenatide QW
to other GLP-1 RAs were statistically significant
for change in HbA1c. No statistically
significant differences in change in weight,
systolic blood pressure, risk of nausea or
discontinuation due to adverse events were
observed for exenatide QW versus other GLP-1
RAs.
Conclusion: Exenatide QW demonstrated
similar effectiveness and tolerability compared
to other GLP-1 RAs, for the treatment of T2DM
in adults inadequately controlled on metformin
alone.
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-016-0155-1)
contains supplementary material, which is available to
authorized users.
S. Kayaniyil (&)  H. A. Bennett




ICON Health Economics and Epidemiology,
Vancouver, BC, Canada
K. Johnsson  B. Kartman
AstraZeneca, Mo¨lndal, Sweden
A. Shaunik  S. Grandy
AstraZeneca, Gaithersburg, MD, USA
Diabetes Ther (2016) 7:27–43
DOI 10.1007/s13300-016-0155-1
Keywords: Exenatide once weekly; GLP-1
receptor agonist; Network meta-analysis; Type
2 diabetes
INTRODUCTION
Achieving and maintaining glycemic control is
the primary goal in the management of type 2
diabetes mellitus (T2DM). Patients are
encouraged to adopt a healthy diet and
increase their exercise; however, for patients
who do not achieve glycemic control following
lifestyle changes, oral antidiabetic agents are
typically prescribed. Therapy is initiated with
metformin, and other agents are added to the
treatment regimen as necessary, to achieve the
desired level of glycemic control [1].
Glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) are a class of glucose-lowering
agents used in the treatment of T2DM. The
addition of a GLP-1 RA is one of the
recommended injectable approaches for
patients who are inadequately controlled on
metformin monotherapy [1].
Exenatide is a GLP-1 RA approved for the
management of glycemic control among
individuals with T2DM and is currently
marketed in two formulations: a solution for
twice-daily injection providing either 5 or 10 lg
of exenatide [exenatide twice daily (BID)] and a
prolonged-release once weekly (QW) injection
that provides 2 mg of exenatide (exenatide
QW). The long-acting formulation contains
the active ingredient of the original exenatide
BID formulation dispersed in microspheres of
medical-grade poly-(d,l-lactide-co-glycolide) in
an aqueous formulation [2]. Exenatide BID was
the first GLP-1 RA approved in the twice-daily
formulation, and exenatide QW was the first
GLP-1 RA approved in the once weekly setting
[3]. Other GLP-1 RAs administered QW that
have since been developed include albiglutide
and dulaglutide, whereas liraglutide and
lixisenatide are administered once daily (QD).
Overall, there are now several GLP-1 RAs on the
market, with different dosing, and some
evidence suggestive of differences in potencies
[4–6]. Exenatide QW is expected to be
associated with greater adherence and
compliance than daily dosing, which could in
turn translate into increased efficacy. As such, a
study that estimates the relative efficacy and
tolerability of exenatide QW compared to the
existing GLP-1 RAs that have been developed is
needed and would be valuable to investigate.
The efficacy and tolerability of exenatide in
its QW formulation has been demonstrated in
randomized controlled trials (RCT) within the
DURATION clinical trial program [7–10] and
real-world evidence studies [11–13]. Apart from
the direct comparison of exenatide QW to
exenatide BID [DURATION 1
(ClinicalTrials.gov identifier, NCT00308139)
and DURATION-5 (ClinicalTrials.gov identifier,
NCT00877890) trials] [7–9], there was one other
trial [DURATION-6 trial (ClinicalTrials.gov
identifier, NCT01029886)] where exenatide
QW was directly compared to another GLP-1
RA [10]. In the DURATION-6 trial, the efficacy
and safety of exenatide QW was compared to
liraglutide 1.8 mg QD in patients with T2DM
treatment with lifestyle modification and one
or more oral antihyperglycemic agents [10].
Newer GLP-1 RAs (albiglutide, dulaglutide and
lixisenatide) have not been compared directly
to exenatide QW.
In the absence of head-to-head evidence
within a clinical trial setting, the efficacy and
tolerability of exenatide 2 mg QW, relative to
other GLP-1 RAs, can be estimated using both
direct and indirect evidence within a network
meta-analysis (NMA) [14, 15]. Where limited
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direct evidence does exist, NMAs allow pooling
direct and indirect evidence together in a single
analysis. The technique is based on the
assumption that, on a suitable scale, one can
add and subtract the within-trial estimates of
relative treatment effects to obtain indirect
evidence. In this case, the difference in effect
between treatments A and B equals the
difference in effects between treatments A and
C and B and C [14, 16].
The objective of this study was to estimate
the relative clinical efficacy and tolerability of
exenatide QW, compared to GLP-1 RAs
approved in the US and/or Europe, for the
treatment of T2DM for patients who fail to
achieve glycemic control on metformin
monotherapy. Efficacy outcomes considered
were mean change from baseline for glycated
hemoglobin (HbA1c) (%), weight (kg) and
systolic blood pressure (SBP) (mmHg) and
proportion of patients achieving glycemic
target (HbA1c\7% and B7%) at 24 ± 6 weeks.
Tolerability was considered by estimating the
relative odds of experiencing nausea or of




A systematic literature review (SLR) was
conducted to identify RCTs to inform the
NMA. EMBASE, MEDLINE, and the Cochrane
Central Register of Controlled Trials were
searched from database inception to October
2014. PubMed was searched from August to
October 2014, to identify new studies not
indexed in EMBASE/MEDLINE. Conference
abstracts from the European Association of the
Study of Diabetes (EASD) 49th Annual Meeting
(2013), and the American Diabetes Association
(ADA) 73rd (2013) and 74th (2014) Scientific
Sessions were searched to identify studies ahead
of full publication. Full search syntax is
available in the supplementary material
(Table S1). All searches were limited to English
language publications.
RCTs suitable for inclusion in the review
were selected using strict predefined inclusion/
exclusion criteria based on the population,
intervention, comparators, outcomes and
study design (PICOS) approach recommended
by the Cochrane Collaboration [17]. Key
inclusion criteria were as follows: RCTs that
examined the use of GLP-1 RAs at doses
approved in the US and/or Europe for the
treatment of T2DM (albiglutide 30 mg QW,
albiglutide 50 mg QW, dulaglutide 0.75 mg
QW, dulaglutide 1.5 mg QW, exenatide 5 lg
BID, exenatide 10 lg BID, exenatide 2 mg QW,
liraglutide 1.2 mg QD, liraglutide 1.8 mg QD, or
lixisenatide 20 lg QD), each as add-on therapy
to metformin monotherapy only, for the
treatment of T2DM, in adults (aged over
18 years) who had inadequately controlled
glycemia following treatment with metformin
monotherapy. Outcomes were to be reported at
24 ± 6 weeks. This time period was deemed long
enough to capture all outcomes of interest and
allow for the inclusion of the largest body of
evidence. Longer duration studies which
reported outcomes at 24 ± 6 weeks were also
eligible for inclusion in the review. Key
exclusion criteria were as follows: RCTs that
specifically examined patients with renal
impairment, involved monotherapy treatment
only, or where change in body weight was the
primary outcome.
The GLP-1 RA clinical programs differed
largely in terms of background medications
allowed during the trial and patients previous
use of antidiabetic agents. To minimize
heterogeneity of the population included in
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the NMA, to account for different efficacies of
various antihyperglycemic agents [18–20], and
to ensure similarity regarding the population’s
clinical spectrum of T2DM, at least 80% of
patients in each treatment arm within an
eligible trial must have received background
therapy consisting only of metformin
monotherapy during the trial; and at least
80% of patients in all treatment arms within
the trial must have metformin monotherapy or
diet and exercise as the pre-trial diabetes
management method.
Two reviewers independently determined
whether articles met inclusion criteria.
Abstracts of all identified articles were first
assessed by each reviewer. Full text articles
were obtained for any articles where inclusion
could not be determined from the abstract
alone. Discrepancies between reviewers were
resolved by consensus—a third reviewer
adjudicated unresolved disputes; the judgment
of the third reviewer was considered final. Data
extraction was performed by one analyst who
extracted data elements from each included
RCT, and line verification of the extraction
fields was performed by a second reviewer.
Discrepancies between reviewers were resolved
as described above.
The Cochrane Collaboration’s tool for
assessing risk of bias [21] was used to assess
the quality of the included RCTs. Two reviewers
independently assessed the quality of included
studies. A third party resolved disagreement in
the manner as described for study selection.
Statistical Methods
Mean values and associated measures of
variability [variance, standard deviation,
standard error (SE) or confidence interval (CI)]
were extracted for continuous endpoints.
Where measures of variability were not
reported, the SE was imputed by borrowing
information from other studies included in the
review, using methods recommended by the
Cochrane handbook for systematic reviews of
interventions [17]. Counts or proportion of
events was extracted for binary endpoints.
Statistical analyses, other than the NMA were
conducted using the statistical package Stata 12
(StataCorp, College Station, Texas, US).
The NMA was fitted by Markov Chain Monte
Carlo techniques using the statistical package
WinBUGS, version 1.4.3. (Cambridge, United
Kingdom) [22] Code for the NMA was based on
that recommended by the National Institute for
Health and Clinical Excellence Decision
Support Unit [23]. Non-informative (or
‘‘vague’’) prior distributions were used to
ensure estimates of treatment effects were
informed by the trial data rather than by the
choice of prior distribution.
For each outcome, random effects (RE) and
fixed effect (FE) models were run. The a priori
choice of model was an RE model, based on the
assumption that there is not one true effect.
A FE model was selected over an RE model by
making considerations of the following aspects:
(1) model fit among the FE and RE models,
based on the deviance information criteria
(DIC), which quantifies the trade-off between
the goodness of fit of the data to the model and
the complexity of the model, with a lower DIC
value indicating a better fit; and (2) whether the
posterior distribution of the between-studies
variance was updated from the prior
distribution with reasonable precision (i.e.,
credible interval (CrI) around between-studies
variance was narrow enough that results from
the RE model were still informative). If the
between-studies variance was not appropriately
updated, particularly because of having a sparse
network of evidence (i.e., model was unable to
estimate this parameter with the available
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evidence base), the FE model was selected over
the RE model, when DIC values were
comparable. However, in these cases, it is
encouraged to look at results from both the FE
and RE model and understand that the true
value is likely between these findings.
Meta-regressions were conducted to explore
heterogeneity in treatment effects due to
differences in baseline values. These models
were not deemed robust, as there were not
enough data points informing the covariate
effect (i.e., comparisons against the reference
treatment informed by more than one study).
The results from these models are hence not
presented. Mean changes in HbA1c, weight, and
SBP were analyzed using the mean difference
scale; proportion of subjects achieving glycemic
target, proportion of subjects experiencing
nausea or who discontinued due to adverse
events were analyzed on an odds ratio scale. Key
elements of patient population and baseline risk
were summarized in boxplots, to evaluate
heterogeneity in the network [16, 24].
Each model was coded, analyzed,
summarized using graphical and summary
tables, validated, and reported. Model
convergence was checked by examining
caterpillar and density plots. The NMA
presents results for GLP-1 RAs included in the
network; antihyperglycemic agents that
provided indirect evidence were not
considered agents of interest and results for
those agents are not presented.
For studies that presented endpoints in
graph format only, values were derived by
digitizing the graph, using the DigitizeIt
program, version 1.5 (DigitizeIt, Braunschweig,
Germany). Endpoints reported at week 24 were
preferred, but data were acceptable if reported
between 18 and 30 weeks post-randomization.
To generate estimates on the absolute scale,
the mean reported absolute effect across the
included placebo arms within each network was
calculated and used as the anchor point
(liraglutide 1.2 mg QD was used for the SBP
network). These anchor values were then added
to the relative treatment effects estimated by
the NMA.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of




The SLR identified 662 articles of which 14 RCTs
met criteria for inclusion in the NMA [25–38].
A PRISMA flow chart summarizing search results
and study selection is provided in the
supplementary material (Figure S1 in the
supplementary material). Table 1 presents
study and patient characteristics from the 14
RCTs included in the NMA.
The mean age of participants ranged from 42.7
to 58.2 years, average duration of T2DM ranged
from 4.4 to 8.2 years, and baseline HbA1c ranged
from 7.8% to 8.9%. Boxplots for mean age,
duration of T2DM, HbA1c and weight at baseline,
by treatment comparators, are presented in the
supplementary material (Figure S2).
The overall quality of the included trials in
the network was good. The generation of the
randomization sequence and concealment of
blinding was adequate, when reported;
however, this was not always described by
authors. Eight studies were open-label, as this
design is often used for drugs with injections,
and for therapeutic monitoring. Most of the
studies reported similar characteristics between
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treatment groups at baseline. Only two studies
[25, 38] noted differences in gender proportions
at baseline between treatment groups, but
significance was not tested.
The endpoint data for the individual trials
included in the NMA is presented in the
supplementary material; Table S2 (HbA1c,
weight and SBP), Table S3 (proportion of
patients achieving glycemic target), and
Table S4 (tolerability data).
NMA
Characteristics of model fit for all outcomes
included in the NMA are presented in the
supplementary material (Table S5).
All 14 trials provided evidence for the
network of mean change in HbA1c from
baseline (Figure S3 in the supplementary
material). The relative effect sizes are
presented in Table 2. All regimens performed
significantly better than placebo at reducing
HbA1c levels; point estimates varied from
-0.42% for exenatide 5 lg BID to -1.09%
for exenatide QW and dulaglutide 1.5 mg
QW. For the comparisons of exenatide QW
against other active agents for the HbA1c
endpoint, exenatide QW was significantly
better than lixisenatide 20 lg QD (mean
-0.59%, 95% CrI -1.15, -0.03). The
remaining comparisons of exenatide QW to
the other GLP-1 RAs were not statistically
different for HbA1c change.
Ten trials reported the proportion of subjects
achieving glycemic target and definitions
described as HbA1c \7% and B7% were
considered for analysis (Figure S4 in the
supplementary material). There were no
statistically significant differences observed for
exenatide QW versus the other GLP-1 RAs
(Table 3).
All 14 included RCTs provided evidence for
the network of mean change in weight from
baseline (Figure S5 in the supplementary
material). All GLP-1 RA treatment arms were
associated with a reduction in weight from
Table 2 Relative effect sizes for mean change in HbA1c
Regimen Change in HbA1c from baseline (%)
Random effects model Fixed effect model
All vs. placebo
Mean (95% CrI)




Exenatide QW vs. all
Mean (95% CrI)
Placebo N/A -1.09 (-1.65, -0.53)* N/A -1.19 (-1.52, -0.85)*
Dulaglutide 1.5 mg QW -1.09 (-1.75, -0.43)* 0.00 (-0.72, 0.72) -1.19 (-1.50, -0.87)* 0.00 (-0.33, 0.33)
Liraglutide 1.8 mg QD -1.03 (-1.55, -0.51)* -0.06 (-0.65, 0.54) -1.13 (-1.41, -0.84)* -0.06 (-0.36, 0.24)
Exenatide 10 lg BID -0.75 (-1.11, -0.43)* -0.34 (-0.95, 0.31) -0.79 (-0.98, -0.61)* -0.39 (-0.73, -0.06)*
Liraglutide 1.2 mg QD -0.71 (-1.16, -0.26)* -0.38 (-0.92, 0.16) -0.81 (-1.07, -0.55)* -0.38 (-0.66, -0.10)*
Albiglutide 30 mg QW -0.69 (-1.11, -0.28)* -0.39 (-1.00, 0.20) -0.79 (-1.04, -0.55)* -0.39 (-0.69, -0.10)*
Lixisenatide 20 lg QD -0.50 (-0.75, -0.25)* -0.59 (-1.15, -0.03)* -0.62 (-0.81, -0.42)* -0.57 (-0.89, -0.25)*
Exenatide 5 lg BID -0.42 (-0.87, 0.00)* -0.66 (-1.35, 0.05) -0.40 (-0.65, -0.15)* -0.79 (-1.20, -0.37)*
Exenatide 2 mg QW -1.09 (-1.65, -0.53)* N/A -1.19 (-1.52, -0.85)* N/A
BID twice daily, CrI credible interval, HbA1c glycated hemoglobin, N/A not applicable, QD once daily, QW once weekly
* Statistically signiﬁcant difference
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baseline (absolute change). Only exenatide
10 lg BID was significantly better than placebo
in weight change from baseline (Table 4). There
was no statistically significant difference in
weight change between exenatide QW and the
other GLP-1 RAs.
Table 3 Relative effect sizes for odds of achieving glycemic target
Regimen Odds of achieving glycemic target (£7%)
Random effects model Fixed effect model









Placebo N/A 7.92 (0.76, 85.71) N/A 7.68 (3.86, 15.44)*
Dulaglutide 1.5 mg QW 10.55 (0.68, 174.34) 0.75 (0.06, 9.88) 9.96 (4.80, 20.74)* 0.77 (0.39, 1.53)
Liraglutide 1.8 mg QD 10.38 (1.06, 108.20)* 0.76 (0.10, 6.02) 9.82 (5.17, 18.65)* 0.78 (0.44, 1.41)
Liraglutide 1.2 mg QD 5.76 (0.70, 49.75) 1.38 (0.21, 8.95) 5.48 (3.03, 9.94)* 1.40 (0.83, 2.38)
Exenatide 10 lg BID 3.75 (1.19, 13.71)* 2.11 (0.17, 23.71) 3.27 (2.28, 4.74)* 2.35 (1.17, 4.73)*
Lixisenatide 20 lg QD 2.91 (1.12, 7.83)* 2.72 (0.31, 23.43) 2.82 (2.14, 3.74)* 2.72 (1.44, 5.16)*
Exenatide 5 lg BID 2.45 (0.57, 12.07) 3.23 (0.21, 46.76) 2.16 (1.19, 3.89)* 3.56 (1.50, 8.50)*
Exenatide 2 mg QW 7.92 (0.76, 85.71) N/A 7.68 (3.86, 15.44)* N/A
BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically signiﬁcant difference
Table 4 Relative effect sizes for mean change in weight (kg)
Regimen Change in weight from baseline (kg)
Random effects model Fixed effect model
All vs. placebo Exenatide
QW vs. all
All vs. placebo Exenatide
QW vs. all
Mean (95% CrI) Mean (95% CrI) Mean (95% CrI) Mean (95% CrI)
Placebo N/A -1.00 (-3.48, 1.33) N/A -0.89 (-2.19, 0.40)
Exenatide 10 lg BID -2.05 (-3.48, -0.83)* 1.05 (-1.50, 3.64) -1.92 (-2.58, -1.25)* 1.03 (-0.31, 2.35)
Liraglutide 1.8 mg QD -2.05 (-4.41, 0.16) 1.06 (-1.24, 3.31) -1.97 (-3.14, -0.80)* 1.08 (-0.05, 2.21)
Liraglutide 1.2 mg QD -1.68 (-3.79, 0.31) 0.68 (-1.38, 2.70) -1.60 (-2.65, -0.55)* 0.71 (-0.30, 1.71)
Dulaglutide 1.5 mg QW -1.34 (-4.17, 1.37) 0.35 (-2.43, 3.10) -1.26 (-2.57, 0.06) 0.37 (-0.92, 1.65)
Exenatide 5 lg BID -1.15 (-2.80, 0.48) 0.15 (-2.77, 2.92) -1.15 (-2.09, -0.19)* 0.25 (-1.33, 1.83)
Lixisenatide 20 lg QD -0.80 (-1.87, 0.15) -0.20 (-2.49, 2.03) -0.71 (-1.20, -0.23)* -0.18 (-1.38, 1.03)
Albiglutide 30 mg QW -0.20 (-3.49, 3.00) -0.80 (-4.25, 2.65) -0.11 (-2.93, 2.72) -0.78 (-3.67, 2.09)
Exenatide 2 mg QW -1.00 (-3.48, 1.33) N/A -0.89 (-2.19, 0.40) N/A
BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically signiﬁcant difference
Diabetes Ther (2016) 7:27–43 35
A total of five trials provided evidence for
mean change in SBP from baseline, for the
following regimens: exenatide QW, dulaglutide
1.5 mg QW, and liraglutide 1.2 and 1.8 mg QD
(Figure S6 in the supplementary material). The
Get-Goal X trial [37], which evaluated exenatide
10 lg BID vs. lixisenatide 20 lg QD had to be
excluded, as these agents were disconnected
from the rest of the network (i.e., no direct
comparisons were available between either
exenatide 10 lg BID or lixisenatide 20 lg QD
versus any of the other agents). None of the
trials that reported change in SBP included a
placebo arm, so liraglutide 1.2 mg QD was
chosen as the reference treatment. Exenatide
QW demonstrated a trend towards greater SBP
reduction against all other GLP-1 RAs in the
network, although these comparisons did not
achieve statistically significant results (Table 5).
A total of 11 RCTs reported nausea as an
adverse event, but one trial by Gallwitz et al.
[35] was excluded as information on this
outcome was only provided in one treatment
arm (Figure S7 in the supplementary material).
Exenatide QW exhibited a trend towards a
lower risk of nausea compared to all GLP-1
RAs except exenatide 5 lg BID, but results were
not statistically significant (point estimates of
the odds ratios ranged from 0.29 vs. dulaglutide
1.5 mg QW, to 0.98 vs. lixisenatide 20 lg QD;
and 1.73 for the comparison against exenatide
5 lg BID) (Table 6).
Thirteen RCTs reported the number of
subjects discontinuing treatment due to
adverse events (Figure S8 in the supplementary
material). The endpoint estimate for risk of
discontinuation due to adverse events indicated
a beneficial effect for exenatide QW compared
to dulaglutide 1.5 mg QW, and liraglutide
1.2 mg and 1.8 mg QD, but none of these
differences were statistically significant
(Table 7).
Estimates on the absolute scale are presented
in the supplementary material (Table S6).
DISCUSSION
The position statement of the ADA and the
EASD recommends the addition of GLP-1 RAs as
a therapeutic option for patients with T2DM
who are inadequately controlled on metformin
monotherapy, with consideration of individual
patient-related factors [1]. This study presents
the results of an NMA that investigated the
relative efficacy and tolerability of GLP-1 RAs,
and in particular examined how exenatide QW,
Table 5 Relative effect sizes from the ﬁxed effect model for mean change in systolic blood pressure (mmHg)
Regimen Change in SBP from baseline (mmHg)
Fixed effect model
All vs. liraglutide 1.2 mg QD Exenatide QW vs. all
Mean (95% CrI) Mean (95% CrI)
Liraglutide 1.2 mg QD N/A -2.13 (-5.22, 0.96)
Dulaglutide 1.5 mg QW 0.27 (-2.72, 3.25) -2.40 (-6.41, 1.62)
Liraglutide 1.8 mg QD 0.81 (-1.46, 3.08) -2.94 (-6.45, 0.58)
Exenatide 2 mg QW -2.13 (-5.22, 0.96) N/A
CrI credible interval, N/A not applicable, QD once daily, QW once weekly, SBP systolic blood pressure
* Statistically signiﬁcant difference. Note: the random effects model is not reported as there was not enough information to
estimate the between-study standard deviation
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the first once weekly GLP-1 RA, compared to
other existing GLP-1 RAs. Overall, the results of
this study suggest that exenatide QW has a
similar effectiveness and tolerability profile
compared to other members of its class, for
the treatment of adults with T2DM
inadequately controlled on metformin
monotherapy, with some evidence of
Table 7 Relative effect sizes for risk of treatment discontinuation due to adverse events
Regimen Risk of treatment discontinuation due to AEs
Fixed effect model Random effects model









Placebo N/A 12.78 (1.82, 97.03)* N/A 13.01 (0.46, 342.41)
Exenatide 5 lg BID 2.90 (0.64, 12.43) 4.41 (0.48, 43.64) 3.49 (0.36, 48.96) 3.73 (0.07, 141.17)
Lixisenatide 20 lg QD 4.45 (2.07, 10.79)* 2.87 (0.49, 18.25) 4.76 (1.26, 20.84)* 2.73 (0.12, 51.16)
Exenatide 10 lg BID 5.91 (2.51, 15.36)* 2.16 (0.34, 14.60) 6.97 (1.42, 52.20)* 1.87 (0.05, 46.25)
Liraglutide 1.2 mg QD 22.20 (3.94, 134.29)* 0.58 (0.16, 2.21) 23.17 (1.36, 474.85)* 0.56 (0.04, 6.75)
Liraglutide 1.8 mg QD 23.88 (3.87, 157.59)* 0.53 (0.13, 2.34) 24.68 (1.02, 675.87)* 0.53 (0.03, 8.42)
Dulaglutide 1.5 mg QW 23.95 (3.41, 178.57)* 0.53 (0.11, 2.69) 24.95 (0.63, 1187.97) 0.52 (0.01, 15.53)
Exenatide 2 mg QW 12.78 (1.82, 97.03)* N/A 13.01 (0.46, 342.41) N/A
AE adverse event, BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically signiﬁcant difference
Table 6 Relative effect sizes for risk of nausea
Regimen Risk of nausea
Random effects model Fixed effect model









Placebo N/A 4.37 (0.06, 361.04) N/A 3.77 (1.35, 10.69)*
Exenatide 5 lg BID 2.53 (0.18, 36.05) 1.73 (0.01, 246.66) 2.82 (1.62, 4.96)* 1.33 (0.43, 4.11)
Lixisenatide 20 lg QD 4.45 (0.78, 27.49) 0.98 (0.02, 52.67) 3.86 (2.69, 5.61)* 0.98 (0.37, 2.61)
Exenatide 10 lg BID 4.69 (0.54, 40.69) 0.93 (0.01, 86.57) 5.22 (3.48, 7.92)* 0.72 (0.26, 2.01)
Liraglutide 1.2 mg QD 9.89 (0.21, 490.78) 0.44 (0.01, 13.72) 8.50 (3.19, 22.22)* 0.44 (0.20, 1.00)
Liraglutide 1.8 mg QD 12.96 (0.18, 975.55) 0.34 (0.01, 15.75) 11.60 (4.17, 31.79)* 0.32 (0.14, 0.77)*
Dulaglutide 1.5 mg QW 15.13 (0.09, 2563.17) 0.29 (0.00, 33.99) 13.56 (4.52, 40.37)* 0.28 (0.11, 0.73)*
Exenatide 2 mg QW 4.37 (0.06, 361.04) N/A 3.77 (1.35, 10.69)* N/A
BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically signiﬁcant difference
Diabetes Ther (2016) 7:27–43 37
improved HbA1c control over lixisenatide, and,
though not significant, trends toward
improvement in SBP and reduced risk of
nausea against all non-exenatide GLP-1 RAs.
Few differences in efficacy between the
GLP-1 RAs, as add-on to metformin, were
found. Exenatide QW was significantly better
than lixisenatide 20 lg QD in reducing HbA1c,
and comparable to other GLP-1 RAs for change
in HbA1c. Exenatide QW demonstrated a trend
towards favorable results in the proportion of
patients achieving glycemic target compared to
both exenatide BID regimens, liraglutide 1.2 mg
QD and lixisenatide 20 lg QD, although these
comparisons were not statistically significant.
Change in weight from baseline was
comparable for all GLP-1 RAs. The significant
difference between exenatide QW and
lixisenatide QD in HbA1c reduction, may be
partially explained by the fact that the QW
dosing of exenatide provides better glycemic
control than lixisenatide, a short-acting agent,
which is administered once daily and therefore,
does not have an effect over 24 h.
Published NMAs on GLP-1 RAs [18, 39, 40]
have reported few differences between
individual therapies for the outcomes
examined [18, 40]. Scott et al., found no
statistically significant differences for glycemic
control between exenatide QW and liraglutide
(1.2 and 1.8 mg) [18]. A recent NMA, presented
as a poster, did report that exenatide QW was
associated with a greater reduction in HbA1c
compared to dulaglutide 1.5 mg QW in the
add-on to metformin network, but differences
were not statistically significant [39]. In the
current study, however, results indicated that
exenatide QW was significantly better than
lixisenatide 20 lg QD in reducing HbA1c, and
comparable to other GLP-1 RAs for change in
HbA1c. Another NMA [40] reported that
exenatide QW, exenatide 10 mg BID, and
liraglutide 1.8 mg QD ranked as the top three
agents in terms of weight reduction compared
to traditional hypoglycemic agents. In the
present NMA, overall change in weight was
comparable across all GLP-1 RAs. However, it is
important to note that the current study relied
upon a different evidence base than previous
NMAs, with study duration restricted to
24 ± 6 weeks and the inclusion of any GLP-1
RA at licensed doses.
Based on direct head-to-head trials,
researchers have reported significant differences
between some GLP-1 RAs. In particular, in the
DURATION-1 and DURATION-5 trials, exenatide
QW was found to have superior efficacy in
HbA1c reduction compared to exenatide BID
[8, 9]. In the DURATION-6 trial, the reduction in
HbA1c was significantly greater with liraglutide
1.8 mg QD treatment compared to exenatide
QW (treatment difference for exenatide minus
liraglutide was 0.21%, 95% CI 0.08–0.33) [10].
Yet, these trials were not included in the present
NMA as patients in these trials were on a variety
of oral antihyperglycemic agents prior to study
entry and continued these throughout the trial,
suggesting likely differences in disease severity
compared to a population largely on metformin
monotherapy.
Real-world evidence of the clinical
effectiveness of GLP-1 RAs has been provided
by retrospective studies [11–13]. For change in
HbA1c from baseline, the efficacy has been
reported to be comparable between liraglutide
QD and exenatide QW [13], as well as liraglutide
QD and exenatide BID [11]. Results of the
current NMA also found no differences in
HbA1c change between liraglutide QD and
exenatide QW. Although HbA1c change
between liraglutide QD and exenatide BID was
not directly compared, point estimates were
similar, particularly for liraglutide 1.2 mg QD
and exenatide 10 lg BID. One study has
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reported liraglutide to be more efficacious than
exenatide BID in reducing HbA1c [12].
However, these studies rely upon the
availability of data in medical databases and
thus by their study design, may inherently be
subject to confounding and bias that is absent
from RCTs.
Previous trials have reported that exenatide
QW was associated with less frequent
mild-to-moderate nausea compared to
exenatide BID [8, 9, 41]. In addition, exenatide
QW has been previously reported to be
associated with fewer treatment
discontinuations due to adverse events
compared to liraglutide 1.8 mg QD [10]. These
findings are in line with the design of exenatide
QW, which was developed to provide better
tolerability given its gradual titration [42].
However, results in the current study indicated
that exenatide QW was comparable to other
GLP-1 RAs in the network for both nausea and
treatment discontinuation due to AEs. The lack
of any significant differences in these results was
likely due to the limited evidence base and the
low frequency of discontinuation due to AEs in
the included trials. Yet, a recent pooled analysis
of eight RCTs reported a similar safety and
tolerability profile for exenatide QW compared
to exenatide BID and liraglutide QD [43]. Results
in the current NMA indicated a higher risk of
nausea and treatment discontinuation due to
AEs with exenatide QW compared to exenatide
5 lg BID, although these differences were not
statistically significant.
Strengths and Limitations
A major strength of this study was the
comparison of exenatide QW to GLP-1 RAs
(albiglutide 30 mg QW, dulaglutide 1.5 mg QW,
exenatide 5 lg and 10 lg BID, liraglutide 1.2 mg
and 1.8 mg QD, and lixisenatide 20 lg QD)
approved for use in the US and/or Europe that
has not been investigated in RCTs. In addition,
the current study included an examination of
several efficacy and tolerability outcomes.
Another key strength is the strict inclusion
criteria developed for the study. Eligible RCTs
were required to include at least 80% of patients
who had failed metformin monotherapy prior
to study entry, and received a GLP-1 RA as
add-on to metformin during the trial. To
minimize heterogeneity in the network, there
were several trials that did not meet these
criteria; in particular, eight exenatide QW
trials [8–10, 44–48] did not meet these criteria
and were therefore excluded from the NMA. In
fact, this stringent inclusion/exclusion criteria
may have led to the exclusion of treatments
that may have formed indirect comparisons to
the treatments of interest which could have
influenced the results. However, these higher
order indirect comparisons would also have
contributed less weight to the analysis [49].
There are several potential limitations of the
analysis. First, baseline characteristics such as
gender and ethnicity were not extracted, and
there may be potential differences in the patient
population based on these characteristics.
However, it is unlikely that such
characteristics would result in differences in
clinical outcomes examined in this study.
Second, physical activity and diet are often
not reported in the publications and the impact
of those components of care cannot be
investigated. Third, there are several
methodological differences among the trials
including incorporation of double-blinded
design and titration schedules. Fourth, the
sparse network of evidence informing the
analyses led to considerable uncertainty
around estimates of between-study variance
for all endpoints under the RE models (14
trials informing 16 comparisons). The limited
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evidence base was particularly evident for SBP.
Finally, aggregate, study-level summaries
provided estimates for inclusion in the
analysis, and are subject to ecological bias. The
alternative would be to use individual
patient-level data, which were not available.
CONCLUSION
Overall, the GLP-1 RA class is effective in
controlling hyperglycemia and well-tolerated
in patients with T2DM. The results of this
NMA demonstrated that, exenatide QW has
similar effectiveness and tolerability compared
to other GLP-1 RAs, for the treatment of T2DM
in adults inadequately controlled on metformin
alone. The scientific rigor of the conduct of the
SLR and NMA utilized in this study provides
confidence in the robustness of the results.
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